- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02308501
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Have a positive history of ocular allergies and a positive skin test to protocol defined allergens
- Have a positive CAC reaction at Visit 1
- Have a positive conjunctival inflammation score at Visit 1
Exclusion Criteria:
- May not use disallowed medications in specified washout period
- May not have an ocular or system disease the investigator feels with impact subject safety or trial parameters
- May not have active ocular infection
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Lastacaft ®
One drop Lastacaft ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
|
|
|
Placebo komparator: Tears Naturale ®
One drop Tears Naturale ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Conjunctival Inflammation at 1 Hour (+30 Minutes) Post CAC on Day 1
Tidsramme: 1 hour (+30 minutes) post CAC on Day 1
|
Conjunctival Inflammation was assessed by a trained technician post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0 = best [least inflammation] and 4 = worst [most inflammation]). The Conjunctival Inflammation was averaged across all Lastacaft-treated eyes to create the average Lastacaft eye Conjunctival Inflammation score, and the Conjunctival Inflammation score was averaged across all Tears Naturale-treated eyes to create the average Tears Naturale eye Conjunctival Inflammation score. |
1 hour (+30 minutes) post CAC on Day 1
|
|
Conjunctival Inflammation 1 Hour (+30 Minutes) Post CAC on Day 2
Tidsramme: 1 hour (+30 minutes) post CAC on Day 2
|
Conjunctival Inflammation was assessed by a trained technician post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0 = best [least inflammation] and 4 = worst [most inflammation]). The Conjunctival Inflammation was averaged across all Lastacaft-treated eyes to create the average Lastacaft eye Conjunctival Inflammation score, and the Conjunctival Inflammation score was averaged across all Tears Naturale-treated eyes to create the average Tears Naturale eye Conjunctival Inflammation score. |
1 hour (+30 minutes) post CAC on Day 2
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Ocular Itching on Day 1 (15 Minutes Post-study Medication Instillation)
Tidsramme: 15 minutes post-study medication instillation
|
CAC was performed 15 minutes after study medication instillation.
Ocular Itching was assessed by the patient on a 0-4 scale (0 = best [no itching] to 4 = worst [severe itching]).
The ocular itching score was averaged across all Lastacaft-treated eyes to create the average Lastacaft eye ocular itching score, and the ocular itching score was averaged across all Tears Naturale-treated eyes to create the average Tears Naturale eye ocular itching score.
|
15 minutes post-study medication instillation
|
|
Ocular Itching on Day 2 (15 Minutes Post-study Medication Instillation)
Tidsramme: 15 minutes post-study medication instillation
|
CAC was performed 15 minutes after study medication instillation.
Ocular Itching was assessed by the patient on a 0-4 scale (0 = best [no itching] to 4 = worst [severe itching]).
The ocular itching score was averaged across all Lastacaft-treated eyes to create the average Lastacaft eye ocular itching score, and the ocular itching score was averaged across all Tears Naturale-treated eyes to create the average Tears Naturale eye ocular itching score.
|
15 minutes post-study medication instillation
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i immunsystemet
- Overfølsomhet, Umiddelbar
- Øyesykdommer
- Overfølsomhet
- Konjunktivale sykdommer
- Konjunktivitt
- Konjunktivitt, allergisk
- Fysiologiske effekter av legemidler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Histamin H1-antagonister
- Histaminantagonister
- Histaminmidler
- Alkaftadin
Andre studie-ID-numre
- 14-100-0012
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Lastacaft ®
-
Starx Research Center, LLCUkjentAllergisk konjunktivitt | RhinokonjunktivittForente stater
-
AllerganFullførtKonjunktivitt, allergiskKorea, Republikken
-
AllerganFullførtKonjunktivitt, allergiskForente stater
-
Galderma R&DFullført
-
Dong-A ST Co., Ltd.FullførtFunksjonell dyspepsiKorea, Republikken
-
Chong Kun Dang PharmaceuticalFullført
-
Chung-Ang University Hosptial, Chung-Ang University...UkjentFunksjonell dyspepsiKorea, Republikken
-
Sanofi Pasteur, a Sanofi CompanyFullførtPertussis | Difteri | PolioForente stater
-
Sanofi Pasteur, a Sanofi CompanyFullførtPertussisForente stater